Literature DB >> 25294911

T-cell levels are prognostic in mantle cell lymphoma.

Lina Nygren1, Agata M Wasik2, Stefanie Baumgartner-Wennerholm3, Åsa Jeppsson-Ahlberg2, Monika Klimkowska2, Patrik Andersson4, Daren Buhrkuhl5, Birger Christensson2, Eva Kimby3, Björn E Wahlin3, Birgitta Sander6.   

Abstract

PURPOSE: The purpose of this study was to investigate the impact of T-cell subsets on pathologic and clinical features including disease outcome in mantle cell lymphoma (MCL). EXPERIMENTAL
DESIGN: Cell populations were investigated using flow cytometry in diagnostic MCL (n = 153) and reactive (n = 26) lymph node biopsies. Levels of tumor cells, T cells, T-cell subsets, and the CD4:CD8 ratio were assessed and related to pathologic and clinical parameters.
RESULTS: MCL cases with diffuse and nodular histologic subtypes showed lower levels of T cells, especially CD4(+) T cells, than those with mantle zone growth pattern. Both CD3 and CD4 levels were lower in the nodular subtype than in mantle zone (P = 0.007; P = 0.003) and in the diffuse compared with the nodular subtype (P = 0.022; P = 0.015). The CD4:CD8 ratios were inversely correlated to tumor cell proliferation (P = 0.003). Higher levels of CD3(+) and CD4(+) T cells and higher CD4:CD8 ratios were associated with indolent disease (P = 0.043, 0.021, and 0.003 respectively). In univariate analysis, a high CD4:CD8 ratio, but not the histologic subtype, was correlated to longer overall survival (OS). In multivariate analysis, the CD4:CD8 ratio correlated with OS independently of Mantle Cell Lymphoma International Prognostic Index (MIPI) and high p53 expression (P = 0.023).
CONCLUSION: CD3(+), CD8(+), and particularly CD4(+) T-cell levels are higher in indolent MCL and decrease with more aggressive histology as reflected by a diffuse growth pattern. High CD4:CD8 ratio correlated independently of other high-risk prognostic factors with longer OS, suggesting a prognostic role for T cells in MCL. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2014        PMID: 25294911     DOI: 10.1158/1078-0432.CCR-14-0889

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

Review 1.  Mantle cell lymphoma--a spectrum from indolent to aggressive disease.

Authors:  Birgitta Sander; Leticia Quintanilla-Martinez; German Ott; Luc Xerri; Isinsu Kuzu; John K C Chan; Steven H Swerdlow; Elias Campo
Journal:  Virchows Arch       Date:  2015-08-23       Impact factor: 4.064

Review 2.  Targeting The Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic Strategies.

Authors:  Michael R Cook; Kieron Dunleavy
Journal:  Curr Oncol Rep       Date:  2022-04-11       Impact factor: 5.945

Review 3.  New developments in the pathology of malignant lymphoma: a review of the literature published from October 2014-December 2014.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2015-03-07       Impact factor: 0.196

4.  Cytoplasmic expression of C-MYC protein is associated with risk stratification of mantle cell lymphoma.

Authors:  Yi Gong; Xi Zhang; Rui Chen; Yan Wei; Zhongmin Zou; Xinghua Chen
Journal:  PeerJ       Date:  2017-06-13       Impact factor: 2.984

Review 5.  Systematic evaluation of immune regulation and modulation.

Authors:  David F Stroncek; Lisa H Butterfield; Michael A Cannarile; Madhav V Dhodapkar; Tim F Greten; Jean Charles Grivel; David R Kaufman; Heidi H Kong; Firouzeh Korangy; Peter P Lee; Francesco Marincola; Sergio Rutella; Janet C Siebert; Giorgio Trinchieri; Barbara Seliger
Journal:  J Immunother Cancer       Date:  2017-03-21       Impact factor: 13.751

6.  Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients.

Authors:  Gustav Arvidsson; Johan Henriksson; Birgitta Sander; Anthony P Wright
Journal:  Haematologica       Date:  2018-02-15       Impact factor: 9.941

7.  SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma.

Authors:  Patricia Balsas; Luis Veloza; Guillem Clot; Marta Sureda-Gómez; Marta-Leonor Rodríguez; Christos Masaoutis; Gerard Frigola; Alba Navarro; Silvia Beà; Ferran Nadeu; Eva Giné; Armando López-Guillermo; Antonio Martínez; Inmaculada Ribera-Cortada; Pablo Engel; Leticia Quintanilla-Martínez; Wolfram Klapper; Elias Campo; Virginia Amador
Journal:  Blood       Date:  2021-12-02       Impact factor: 22.113

8.  Negative prognostic impact of low absolute CD4+ T cell counts in peripheral blood in mantle cell lymphoma.

Authors:  Xin-Yu Zhang; Ji Xu; Hua-Yuan Zhu; Yan Wang; Li Wang; Lei Fan; Yu-Jie Wu; Jian-Yong Li; Wei Xu
Journal:  Cancer Sci       Date:  2016-09-14       Impact factor: 6.716

Review 9.  Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.

Authors:  Arati A Inamdar; Andre Goy; Nehad M Ayoub; Christen Attia; Lucia Oton; Varun Taruvai; Mark Costales; Yu-Ting Lin; Andrew Pecora; K Stephen Suh
Journal:  Oncotarget       Date:  2016-07-26

10.  Simplified MIPI-B prognostic stratification method can predict the outcome well-retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China.

Authors:  Jing-Song He; Xi Chen; Guo-Qing Wei; Jie Sun; Wei-Yan Zheng; Ji-Min Shi; Wen-Jun Wu; Yi Zhao; Gao-Feng Zheng; He Huang; Zhen Cai
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.